

Hua Medicine



This


H
H M





Copyright © Hua Medicine 2022

Founder & CEO



Li Chen, Ph.D., *Founder & Board Director*

CSO and Founding Director of Roche R&D Center (China), responsible for development of China ' s drug discovery strategy, creation of discovery portfolio and management of operations

Former head of HTC technology at Roche


Adjunct professor at Tongji University, Ph D advisor

Yilei Fu, BS, MBA EMC /Span <</MCID 48/Lang (en-USID 489<</M7.c50n <</MCID 43T.288 Tm2 Tq0.000. reW* nBT/F3 12 Tf1 0 0 1 670.3

[redacted]


IDF 2021

537 Mn Diabetes
Many
Complications



Top 10 Nations

Rank	Country or territory	Total diabetes-related health expenditure in adults (20–79 years)
1	[illegible] America	379.5
2	China	165.3
3	Brazil	42.9
4	Germany	41.3
5	Japan	35.6
6	United Kingdom	23.4
7	France	22.7
8	Mexico	19.9
9	Spain	15.5
10	Italy	14.7



Lost Glucose Homeostasis

TIR in Diabetes Survival

Economic Burden

Source: Cheng YY, Chen L. Global J Obesity, Diabetes and Metabolic Syndrome 2020, 7 018-023
Source: IDF DIABETES ATLAS Tenth edition 2021


Dorzagliatin improves glucose sensitivity and beta cell function as novel mechanism to treat diabetes

- In clinical trials - Dorzagliatin improves β-cell function in T2D in China, and repairs GLP-1 secretion in obese T2D patients in US
- Phase 3 SEED, DAWN studies demonstrated the potential for best homeostasis control for drug naïve and metformin-tolerant T2D patients in China
- Diabetes remission achieved in Dorzagliatin treated drug naïveT2D patients in the DREAM study

- President Dalong Zhu, Ex-President Wenying Yang of Chinese Diabetes Society led SEED and DAWN studies and as 1st authors in back-to-back Nature Medicine (2021 IF: 87.24) on 12th May 2022
- Dr John Buse, former ADA president: A New Class of Drug in Diabetes Toolbox (NMED)
- The news of SEED and DAWN publication in NM were reported or(NMEecuardl)-3(ed52( )28(b)3yr(NMmu(l)-3







1		
2		10
3		-
4		2
5		-
6		-

- Dorzagliatin has been included into a new Expert Opinions on <Evaluation and Protection of beta cell Function in T2D Patients> published on 20th June. The latest SEED and DAWN results and publications were sited in the Opinions.
- Dorzagliatin rescues insulin secretion in rat beta cell, and improves HOMA2-b in type 2 diabetes patients either drug naïve or metformin tolerated.


·规范与指南·


临床专家共识













Copyright © Hua Medicine 2022

- Heterozygous GCK mutation leads MODY-2 disease condition:
  - elevated blood glucose
  - reduced 2nd Phase insulin secretion
- A single dose of Dorzagliatin improves 2nd phase insulin secretion and improves the beta cell glucose sensitivity
- Proof of mechanism of action (MOA) of Dorzagliatin in hyperglycemic clamp study





Source: E Chow, E Ferrannini, J Chan, 2022 ADA 261-OR

Copyright © Hua Medicine 2022



Source Matthew C Riddle, et al. Diabetes Care. 2021 Aug 30;44(10):2438-24

- **RISE Study**: Drug naive T2D and IGT subjects were treated for 12 month with **Metformin (Red), GLP-1 + Metformin (Purple) and Glargine + Metformin (Green)** did not show sustained improvement of beta cell function in 15 Month, 3 months after drug withdraw
- **DiRECT Study**:


- HOMA2-β, HOMA2-IR, disposition index (DI) and IGI (ΔC30/ΔG30) have been improved in all participants after Dorzagliatin treatment during SEED study, which leads to 44% patients achieved glycemic control
- Improvement of HOMA2-β, disposition index (DI) and IGI (ΔC30/ΔG30) is statistically significant and in intensity in the remission group when compared between before and after treatment.

HOMA2-β before and after treatment

HOMA2-IR before and after treatment



Copyright © Hua Medicine 2022




- **Diabetes remission** by early intervention of Dorzagliatin: impact about 100 M diabetes patients
- **Diabetes prevention** by Dorzagliatin for IGT subjects: about 541 M IGT patients worldwide
- **Diabetes complication prevention** by early combination of Dorzagliatin: about 440 M T2D patients have one or more comorbidities

* IDF Diabetes Atlas 10th Edit; Leon Litwak Diabetology & Metabolic Syndrome 2013, 5: 57; Yuanyuan Cheng, Li Chen Global J Obesity, Diabetes and Metabolic Syndrome 2020, 7: 18

Copyright © Hua Medicine 2022


H
H M



Copyright © Hua Medicine 2022

Hua Medicine

Global rights to dorzagliatin composition of matter, chemical process, formulation and




H
H M

Copyright © Hua Medicine 2022

Copyright © Hua Medicine 2022

